Table 1.
Characteristics of patients
| Variable | Number (%) |
|---|---|
| Sex | |
| Male | 23 (92) |
| Female | 2 (8) |
| Cranial metastases | |
| Absent | 9 (36) |
| Present | 16 (64) |
| Bone metastases | |
| Absent | 7 (28) |
| Present | 18 (72) |
| The sequence of second/third-line chemotherapy | |
| Irinotecan/topotecan | 11 (44) |
| Topotecan/irinotecan | 14 (56) |
| Response to chemotherapy just before third-line chemotherapy | |
| Respondera | 16 (64) |
| Nonresponder | 9 (36) |
| Sodium level, mmol/L | |
| <135 | 12 (48) |
| ≥135 | 13 (52) |
| Hemoglobin, g/dL | |
| <11 | 10 (40) |
| ≥11 | 15 (60) |
| LDH | |
| Normal | 9 (36) |
| High | 16 (64) |
Note:
a
Responder defined as patients who showed complete response, partial response, or stable disease.
Abbreviation: LDH, lactate dehydrogenase.